Biotechnology company Immutrin has raised £65 ($86.7) million in Series A financing to help fund its lead asset through clinical proof of concept. Immutrin’s lead asset is targeting ATTR cardiomyopathy, a serious and potentially fatal form of amyloidosis. Amyloidosis is a group of rare, progressive diseases caused by misfolded proteins that aggregate into amyloid fibrils […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!